189 related articles for article (PubMed ID: 34550840)
1. Recent advances in lipopolysaccharide-based glycoconjugate vaccines.
Zhu H; Rollier CS; Pollard AJ
Expert Rev Vaccines; 2021 Dec; 20(12):1515-1538. PubMed ID: 34550840
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of O-polysaccharide chain length regulators in Gram-negative bacteria using the Wzx-/Wzy-dependent pathway enhances production of defined modal length O-polysaccharide polymers for use as haptens in glycoconjugate vaccines.
Hegerle N; Bose J; Ramachandran G; Galen JE; Levine MM; Simon R; Tennant SM
J Appl Microbiol; 2018 Aug; 125(2):575-585. PubMed ID: 29603538
[TBL] [Abstract][Full Text] [Related]
3. Improving protein glycan coupling technology (PGCT) for glycoconjugate vaccine production.
Dow JM; Mauri M; Scott TA; Wren BW
Expert Rev Vaccines; 2020 Jun; 19(6):507-527. PubMed ID: 32627609
[TBL] [Abstract][Full Text] [Related]
4. Advancing Homogeneous Antimicrobial Glycoconjugate Vaccines.
Adamo R
Acc Chem Res; 2017 May; 50(5):1270-1279. PubMed ID: 28463499
[TBL] [Abstract][Full Text] [Related]
5. Impact and Control of Sugar Size in Glycoconjugate Vaccines.
Stefanetti G; MacLennan CA; Micoli F
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234967
[TBL] [Abstract][Full Text] [Related]
6. Strain Selection for Generation of O-Antigen-Based Glycoconjugate Vaccines against Invasive Nontyphoidal Salmonella Disease.
Lanzilao L; Stefanetti G; Saul A; MacLennan CA; Micoli F; Rondini S
PLoS One; 2015; 10(10):e0139847. PubMed ID: 26445460
[TBL] [Abstract][Full Text] [Related]
7. Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends.
Micoli F; Adamo R; Costantino P
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914046
[TBL] [Abstract][Full Text] [Related]
8. Glycoconjugate vaccines: current approaches towards faster vaccine design.
Micoli F; Del Bino L; Alfini R; Carboni F; Romano MR; Adamo R
Expert Rev Vaccines; 2019 Sep; 18(9):881-895. PubMed ID: 31475596
[No Abstract] [Full Text] [Related]
9. Glycoengineered Outer Membrane Vesicles as a Platform for Vaccine Development.
Valguarnera E; Feldman MF
Methods Enzymol; 2017; 597():285-310. PubMed ID: 28935107
[TBL] [Abstract][Full Text] [Related]
10. O-Antigen Extraction, Purification, and Chemical Conjugation to a Carrier Protein.
Micoli F; Giannelli C; Di Benedetto R
Methods Mol Biol; 2021; 2183():267-304. PubMed ID: 32959249
[TBL] [Abstract][Full Text] [Related]
11. Synthetic carbohydrate-based vaccines: challenges and opportunities.
Mettu R; Chen CY; Wu CY
J Biomed Sci; 2020 Jan; 27(1):9. PubMed ID: 31900143
[TBL] [Abstract][Full Text] [Related]
12. Potential targets for next generation antimicrobial glycoconjugate vaccines.
Micoli F; Costantino P; Adamo R
FEMS Microbiol Rev; 2018 May; 42(3):388-423. PubMed ID: 29547971
[TBL] [Abstract][Full Text] [Related]
13. Investigation on Sugar-Protein Connectivity in Salmonella O-Antigen Glycoconjugate Vaccines.
De Benedetto G; Salvini L; Gotta S; Cescutti P; Micoli F
Bioconjug Chem; 2018 May; 29(5):1736-1747. PubMed ID: 29697244
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the production of recombinant glycoconjugate vaccines.
Kay E; Cuccui J; Wren BW
NPJ Vaccines; 2019; 4():16. PubMed ID: 31069118
[TBL] [Abstract][Full Text] [Related]
15. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine.
Phalipon A; Costachel C; Grandjean C; Thuizat A; Guerreiro C; Tanguy M; Nato F; Vulliez-Le Normand B; Bélot F; Wright K; Marcel-Peyre V; Sansonetti PJ; Mulard LA
J Immunol; 2006 Feb; 176(3):1686-94. PubMed ID: 16424198
[TBL] [Abstract][Full Text] [Related]
16. Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs.
Berti F; Micoli F
Curr Opin Immunol; 2020 Aug; 65():42-49. PubMed ID: 32361591
[TBL] [Abstract][Full Text] [Related]
17. Click chemistry compared to thiol chemistry for the synthesis of site-selective glycoconjugate vaccines using CRM
Stefanetti G; Allan M; Usera A; Micoli F
Glycoconj J; 2020 Oct; 37(5):611-622. PubMed ID: 32535667
[TBL] [Abstract][Full Text] [Related]
18. Classical and novel strategies to develop a
Barel LA; Mulard LA
Hum Vaccin Immunother; 2019; 15(6):1338-1356. PubMed ID: 31158047
[No Abstract] [Full Text] [Related]
19. Glycoconjugate vaccines against antimicrobial resistant pathogens.
Sorieul C; Dolce M; Romano MR; Codée J; Adamo R
Expert Rev Vaccines; 2023; 22(1):1055-1078. PubMed ID: 37902243
[TBL] [Abstract][Full Text] [Related]
20. Impact of conjugation chemistry on the immunogenicity of S. Typhimurium conjugate vaccines.
Stefanetti G; Rondini S; Lanzilao L; Saul A; MacLennan CA; Micoli F
Vaccine; 2014 Oct; 32(46):6122-9. PubMed ID: 25192974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
